The Hamps Bio Limited IPO, which opened for subscription on December 13, 2024, has garnered significant attention from investors, fully subscribing on its first day. With a price band set at ₹51 per share and a grey market premium (GMP) reaching ₹40, the IPO is expected to be a lucrative opportunity for retail investors before it closes on December 17, 2024.
Total Box Office Collection
As of now, the Hamps Bio IPO has achieved remarkable subscription levels. The issue was fully subscribed on its opening day with a subscription rate of 10.61 times, indicating strong investor interest. The total issue size is approximately ₹6.22 crore, with 12.2 lakh shares being offered.
Day Wise Subscription Details
Here’s a breakdown of the subscription status as it stands:
| Date | Subscription Status |
|---|---|
| December 13 | 10.61x (Fully Subscribed) |
| December 14 | Awaiting Updates |
| December 15 | Awaiting Updates |
| December 16 | Awaiting Updates |
| December 17 | Closes Today |
Grey Market Premium (GMP)
Currently, Hamps Bio shares are trading at a GMP of ₹40, indicating a potential listing price of around ₹91 per share. This suggests that investors could see a substantial profit of approximately 79% upon listing, which is scheduled for December 20, 2024.
Investment Details
- Price Band: ₹51 per share
- Lot Size: Minimum purchase is set at 2,000 shares, requiring a minimum investment of ₹1,02,000.
- Registrar: Bigshare Services Pvt. Ltd.
- Lead Managers: Marwadi Chandarana Intermediaries Pvt. Ltd.
Company Overview
Hamps Bio Limited specializes in the marketing and distribution of pharmaceutical products, including tablets, syrups, capsules, injectables, and nutritional supplements. The company operates through a network of over 50 distributors and e-commerce platforms like Amazon and Flipkart, ensuring widespread availability of its products across India.
Use of Proceeds
The funds raised through this IPO will primarily be utilized for:
- Purchasing plant and machinery for the FMCG division.
- Enhancing brand visibility and awareness.
- General corporate purposes.
Market Outlook
With the pharmaceutical sector being a crucial part of India’s economy, Hamps Bio’s entry into the market comes at an opportune time. The company’s focus on ethical marketing and distribution aligns with growing consumer demand for healthcare products.
Conclusion
As the Hamps Bio IPO continues to attract investor interest with its strong subscription rates and promising GMP, potential investors have until December 17 to participate in this lucrative offering. With the expected listing date on December 20, all eyes will be on how the stock performs in the market post-IPO.
Disclaimer
The information provided in this article is for informational purposes only and should not be considered as financial advice. Investors are encouraged to conduct their own research or consult with financial advisors before making investment decisions.
